AGL 38.00 Increased By ▲ 0.43 (1.14%)
AIRLINK 131.25 Decreased By ▼ -1.25 (-0.94%)
BOP 5.59 Decreased By ▼ -0.05 (-0.89%)
CNERGY 3.78 Increased By ▲ 0.01 (0.27%)
DCL 8.68 Decreased By ▼ -0.19 (-2.14%)
DFML 40.89 Decreased By ▼ -0.11 (-0.27%)
DGKC 87.30 Decreased By ▼ -2.86 (-3.17%)
FCCL 34.70 Decreased By ▼ -0.38 (-1.08%)
FFBL 65.52 Decreased By ▼ -0.98 (-1.47%)
FFL 10.30 Increased By ▲ 0.15 (1.48%)
HUBC 108.61 Increased By ▲ 2.21 (2.08%)
HUMNL 14.01 Increased By ▲ 0.61 (4.55%)
KEL 4.80 Decreased By ▼ -0.06 (-1.23%)
KOSM 6.82 Decreased By ▼ -0.03 (-0.44%)
MLCF 41.11 Decreased By ▼ -0.69 (-1.65%)
NBP 59.50 Increased By ▲ 0.92 (1.57%)
OGDC 180.25 Decreased By ▼ -1.00 (-0.55%)
PAEL 25.40 Decreased By ▼ -0.30 (-1.17%)
PIBTL 5.89 Increased By ▲ 0.06 (1.03%)
PPL 144.50 Decreased By ▼ -3.90 (-2.63%)
PRL 23.21 Decreased By ▼ -0.01 (-0.04%)
PTC 15.22 Decreased By ▼ -0.02 (-0.13%)
SEARL 67.70 Decreased By ▼ -1.09 (-1.58%)
TELE 7.21 Decreased By ▼ -0.03 (-0.41%)
TOMCL 35.60 Decreased By ▼ -0.40 (-1.11%)
TPLP 7.45 Increased By ▲ 0.05 (0.68%)
TREET 14.10 Decreased By ▼ -0.14 (-0.98%)
TRG 50.45 Decreased By ▼ -0.40 (-0.79%)
UNITY 26.38 Decreased By ▼ -0.02 (-0.08%)
WTL 1.22 Increased By ▲ 0.01 (0.83%)
BR100 9,736 Decreased By -31.8 (-0.33%)
BR30 29,316 Decreased By -84 (-0.29%)
KSE100 91,661 Decreased By -277.2 (-0.3%)
KSE30 28,586 Decreased By -157.5 (-0.55%)

WASHINGTON: The US has begun late stage clinical trials into a drug formulated to fight Covid-19, officials said Tuesday. The medicine is an antibody against the new coronavirus called LY-CoV555, which was identified in the blood sample of a recovered patient by Canada's Abcellera Biologics. It was then developed synthetically for mass production by US-based Lilly Research Laboratories in partnership with Abcellera.

The Phase 3 trial will initially enroll some 300 volunteers around the world who have been hospitalized with mild to moderate Covid-19 with fewer than 13 days of symptoms. Each will be assigned either the medicine, which will be injected intravenously, or a placebo.

Patients will also receive standard care for Covid-19, including the antiviral remdesivir. The new Phase 3 trial is being led by Jens Lundgren, of the University of Copenhagen and Rigshospitalet, and could expand to up to 1,000 people, including the more severely ill, if LY-CoV555 appears safe and effective after the fifth day. The trial's main goal is the patients' sustained recovery for 14 days after release from the hospital.

Comments

Comments are closed.